FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)

被引：0
|
作者：
Le, Xiuning
Spira, Alexander I.
Gadgeel, Shirish M.
Riess, Jonathan W.
Yu, Yan
Zhao, Yanqiu
Cheng, Ying
Juan-Vidal, Oscar
Gao, Bo
Yoh, Kiyotaka
Forster, Martin
Kitazono, Satoru
Hayashi, Hidetoshi
Planchard, David
Jiang, Yong
Baio, Nichole
Kowanetz, Marcin
Leung, William
Hsu, Jerry Y.
Wang, Jie
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] NEXT Oncol Virginia, Fairfax, VA USA
[3] Henry Ford Hlth, Henry Ford Canc Inst, Detroit, MI USA
[4] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
[5] Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
[7] Jilin Canc Hosp, Changchun, Peoples R China
[8] Hosp Univ Politecn La Fe, Valencia, Spain
[9] Blacktown Hosp, Blacktown Canc & Haematol Ctr, Blacktown, NSW, Australia
[10] Natl Canc Ctr Hosp East, Kashiwa, Japan
[11] UCL, Hosp NHS Trust, Canc Inst, London, England
[12] Japanese Fdn Canc Res JFCR, Canc Inst Hosp, Tokyo, Japan
[13] Kindai Univ Hosp, Osaka, Japan
[14] Gustave Roussy, Dept Med Oncol, Thorac Grp, Villejuif, France
[15] Allist Pharmaceut, Shanghai, Peoples R China
[16] ArriVent Biopharma, Newtown, PA USA
[17] ArriVent Biopharma, Burlingame, CA USA
[18] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8666
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations
    Le, Xiuning
    Spira, Alexander
    Gadgeel, Shirish
    Yu, Yan
    Zhao, Yanqiu
    Cheng, Ying
    Riess, Jonathan
    Juan-Vidal, Oscar
    Gao, Bo
    Yoh, Kiyotaka
    Forster, Martin
    Kitazono, Satoru
    Hayashi, Hidetoshi
    Planchard, David
    Jiang, Yong
    Huang, Jack
    Baio, Nichole
    Kowanetz, Marcin
    Wang, Shirley
    Leung, William
    Hsu, Jerry Y.
    Wang, Jie
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [2] Furmonertinib is a brain-penetrant EGFR TKI highly active in uncommon EGFR mutations, including PACC and exon 20 insertions
    Nilsson, Monique B.
    Mounir, Zineb
    Musib, Luna
    He, Junqin
    Yu, Xiaoxing
    Li, Qing
    Luo, Huibing
    Heymach, John V.
    Hsu, Jerry Y.
    Lutzker, Stuart
    Le, Xiuning
    Kowanetz, Marcin
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [3] A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)
    Miura, S.
    Hsia, T.
    Hung, J.
    Jung, H. A.
    Shih, J.
    Park, C.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1115 - S1116
  • [4] Clinicopathologic characteristics of NSCLC patients with uncommon EGFR mutations in Korea
    Lee, Yoo Jung
    Yeo, Chang Dong
    Park, Chan Kwon
    Kim, Sung Kyoung
    Kim, Ju Sang
    Kim, Yong Hyun
    Kim, Jin Woo
    Kim, Seung Joon
    Lee, Sang Haak
    Kang, Hye Seon
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [5] Investigation of age and smoking in NSCLC patients with uncommon EGFR mutations
    Maezawa, Yosuke
    Taguchi, Manato
    Kawakami, Takeshi
    Inui, Toshihide
    Okauchi, Shinichiro
    Numata, Takeshi
    Shiozawa, Toshihiro
    Miyazaki, Kunihiko
    Nakamura, Ryota
    Iguchi, Kesato
    Endo, Takeo
    Sakamoto, Tohru
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    [J]. TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2024, 72 (02): : 107 - 113
  • [6] Clinicopathologic characteristics of NSCLC patients with uncommon EGFR mutations in Korea
    Kang, Hye Seon
    Kim, Kyu Yeon
    Lim, Jeong Uk
    Yeo, Chang Dong
    Kim, Ju Sang
    Kim, Seung Joon
    Lee, Sang Haak
    [J]. RESPIROLOGY, 2023, 28 : 100 - 100
  • [7] EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
    Miura, S.
    Hsia, T-C.
    Hung, J-Y.
    Jung, H. A.
    Shih, J-Y.
    Park, C-K.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S967 - S968
  • [8] Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations
    Passaro, Antonio
    Prelaj, Arsela
    Bonanno, Laura
    Tiseo, Marcello
    Tuzi, Alessandro
    Proto, Claudia
    Chiari, Rita
    Rocco, Danilo
    Genova, Carlo
    Sini, Claudio
    Cortinovis, Diego
    Pilotto, Sara
    Landi, Lorenza
    Bennati, Chiara
    Camerini, Andrea
    Toschi, Luca
    Putzu, Carlo
    Cerea, Giulio
    Spitaleri, Gianluca
    Cappuzzo, Federico
    de Marinis, Filippo
    [J]. CLINICAL LUNG CANCER, 2019, 20 (02) : E186 - E194
  • [9] Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study
    Okuma, Yusuke
    Kubota, Kaoru
    Shimokawa, Mototsugu
    Hashimoto, Kana
    Kawashima, Yosuke
    Sakamoto, Tomohiro
    Wakui, Hiroshi
    Murakami, Shuji
    Okishio, Kyoichi
    Hayashihara, Kenji
    Ohe, Yuichiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] New data on clinical decisions in NSCLC patients with uncommon EGFR mutations
    Wu, Ting-Hui
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2017, 11 (01) : 51 - 55
12345